Trial Outcomes & Findings for Photocil (Topical) for the Treatment of Vitiligo (NCT NCT01992185)

NCT ID: NCT01992185

Last Updated: 2016-03-10

Results Overview

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

15 participants

Primary outcome timeframe

90 days

Results posted on

2016-03-10

Participant Flow

Participant milestones

Participant milestones
Measure
Photocil for Vitiligo
Active Drug - Photocil for Vitiligo Photocil for Vitiligo: Photocil for Vitiligo
Placebo - Sunscreen (SPF 2)
Placebo - Sunscreen (SPF 2) Placebo - Sunscreen (SPF 2): Placebo - Sunscreen (SPF 2)
Overall Study
STARTED
7
8
Overall Study
COMPLETED
7
8
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Photocil (Topical) for the Treatment of Vitiligo

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Photocil for Vitiligo
n=7 Participants
Active Drug - Photocil for Vitiligo Photocil for Vitiligo: Photocil for Vitiligo
Placebo - Sunscreen (SPF 2)
n=8 Participants
Placebo - Sunscreen (SPF 2) Placebo - Sunscreen (SPF 2): Placebo - Sunscreen (SPF 2)
Total
n=15 Participants
Total of all reporting groups
Age, Continuous
38 years
STANDARD_DEVIATION 13.4 • n=99 Participants
35.1 years
STANDARD_DEVIATION 15.2 • n=107 Participants
36.5 years
STANDARD_DEVIATION 13.9 • n=206 Participants
Sex: Female, Male
Female
3 Participants
n=99 Participants
4 Participants
n=107 Participants
7 Participants
n=206 Participants
Sex: Female, Male
Male
4 Participants
n=99 Participants
4 Participants
n=107 Participants
8 Participants
n=206 Participants
Region of Enrollment
United States
7 participants
n=99 Participants
8 participants
n=107 Participants
15 participants
n=206 Participants

PRIMARY outcome

Timeframe: 90 days

Outcome measures

Outcome measures
Measure
Photocil for Vitiligo
n=7 Participants
Active Drug - Photocil for Vitiligo Photocil for Vitiligo: Photocil for Vitiligo
Placebo - Sunscreen (SPF 2)
n=8 Participants
Placebo - Sunscreen (SPF 2) Placebo - Sunscreen (SPF 2): Placebo - Sunscreen (SPF 2)
Percent Repigmentation
48.5 Percent Repigmentation
Standard Deviation 16.8
2.5 Percent Repigmentation
Standard Deviation 7.1

Adverse Events

Photocil for Vitiligo

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Placebo - Sunscreen (SPF 2)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Sharon Keene, MD

Physicians Institute

Phone: (520) 290-5555

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: GT60